Halozyme’s offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring.
The post Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec appeared first on MedCity News.
